Purpose: To identify long peptides (LP) derived from a novel tumor-associated antigen (TAA), kinesin family member 20A (KIF20A), which induce tumor-specific T-helper type 1 (T H 1) cells and CTLs.
Introduction
We recently used genome-wide cDNA microarray analysis to identify a novel tumor-associated antigen (TAA), kinesin family member 20A (KIF20A), which is frequently overexpressed in lung cancer, pancreatic cancer, gastric cancer, bladder cancer, breast cancer, melanoma, and various other malignancies (1) (2) (3) . KIF20A has been reported to be a promising immunotherapeutic target for cancers. Studies have reported that 2 short peptides (SP) derived from KIF20A, KIF20A-A2 , and KIF20A-A24 66-75 stimulated CTLs, which kill cancer cells endogenously expressing KIF20A antigen and that KIF20A-specific CTLs were present in peripheral blood mononuclear cells (PBMC) obtained from patients with pancreatic cancer (1, 4) . Phase I/II clinical trials of cancer immunotherapy for lung cancer, pancreatic cancer, and cholangiocellular carcinoma using KIF20A-derived SP are underway. In these trials, we observed that vaccination with a KIF20A-derived SP induced a KIF20A-specific CTL response and yielded promising results in patients with advanced cancer (manuscript in preparation). Therefore, we propose that KIF20A is an attractive target molecule for cancer immunotherapy. We have attempted to identify LP that induce both antigen-specific CD4 þ helper
T (T H ) cells and CTLs to further develop peptide vaccine immunotherapy.
Tumor-specific T H cells, particularly T-helper type 1 (T H 1) cells, play a critical role in efficient induction of CTL-mediated antitumor immunity (5) . IFN-g produced by T H 1 cells is critical for induction and maintenance of long-lived CTL responses through multiple interactions (6, 7) . IFN-g secreted by T H 1 cells also mediates direct antitumor or antiangiogenic effects (8) . Furthermore, T H cells pave the way for entry of CTLs at the tumor site (9) . Therefore, identification of T H -cell epitopes that can activate tumor-specific T H 1 cells is important for induction of effective tumor immunity in tumor-bearing hosts.
Melief and colleagues recently reported a synthetic LP naturally bearing a CTL epitope as an attractive vaccine compound. Following injection of LP, a patient's dendritic cells take up the LP, process it, and present all possible CTL epitopes and T H -cell epitopes in the context of various HLA class I and class II molecules (10) . In addition, recent clinical studies using a promiscuous telomerase-derived helper-epitope vaccine called GV1001 bearing CTL epitopes, increased survival of cancer patients when combined with radiotherapy and chemotherapy (11, 12) . Thus, we proposed that an ideal peptide vaccine for cancer immunotherapy may be a single polypeptide containing epitopes for both T H 1 cells and CTLs, which are naturally proximal to each other and can be induced simultaneously (10, 13) .
In this study, a recently developed computer algorithm predicting HLA class II-binding peptides and known CTLepitope sequences recognized by HLA-A2 or HLA-A24-restricted CTLs were used to select candidate promiscuous T H -cell epitopes containing the CTL epitopes. Our results show that the predicted LPs triggered T H 1 responses in individuals expressing several common HLA-DR or HLA-DP alleles, and that the KIF20A-LPs bearing CTL epitopes efficiently stimulated KIF20A-specific CTLs.
Materials and Methods

Patients
Blood samples were collected from 16 patients with a head-and-neck malignant tumor (HNMT). The immune responses of T H cells reactive to KIF20A-LPs were investigated. The patients were receiving immunotherapy with TAA-derived CTL-epitope peptides, and were enrolled in 2 peptide vaccine trials. These phase I/II clinical trials of cancer immunotherapy using 3 HLA-A24-binding SPs (clinical-grade 9-10-amino acid-SPs) derived from 3 cancertestis antigens, LY6K (LY6K-A24 177-186 ), IMP-3 (IMP-3-A24 508-516 ), and CDCA1 (CDCA1-A24 56-64 ) were reviewed and approved by the Institutional Review Board of Kumamoto University (Kumamoto, Japan; ref. [14] [15] [16] . This vaccine cocktail did not include KIF20A-derived SPs. All patients with HNMT were selected on the basis of HLA-A24 presence after providing written informed consent. The patients suffered from inoperable advanced HNMT with recurrent or metastatic tumors and were resistant to standard therapy; they were enrolled in the trial under University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) number 000008379 (CTR-8379). The patients with radical resection were enrolled in the trial under UMIN-CTR number 000008380 (CTR-8380). In the latter trial, patients were treated with postoperative peptide vaccine combined with S-1, ifosfamide, or doxorubicin. These clinical trials and analyses are ongoing.
Cell lines
Mouse fibroblast cell lines (L-cells), genetically engineered to express DR4 (DRB1 Fig. S1 and Table S1 ).
Translational Relevance
We recently identified a novel tumor-associated antigen, kinesin family member 20A (KIF20A), overexpressed in various malignancies. Phase I/II clinical trials of immunotherapy for several cancers using a KIF20A-derived CTL epitope are underway. We identified promiscuous KIF20A LPs bearing naturally processed epitopes recognized by CD4 þ T cells and CTLs. KIF20A-LPs stimulated KIF20A-specific CTLs in vitro and in vivo. In addition, KIF20A-LP and a T-helper type 1 (T H 1) cell clone enhanced induction of KIF20A-specific CTLs in vitro. Thus, KIF20A-LPs provide a useful tool for propagation of both T H 1 cells and CTLs. This report also describes the first immunohistochemical detection of KIF20A expression in cases of head-and-neck malignant tumor (HNMT), and the first detection of KIF20A-LPsspecific T H 1 cell responses in patients with HNMT. These findings will support clinical trials of KIF20A peptidebased immunotherapy for various cancers. Human KIF20A-derived SPs presented by HLA-A2  (KIF20A-A2 809-817 ) or HLA-A24 (KIF20A-A24 66-75 ), and 3  LPs (KIF20A 60-84 -LP, KIF20A 494-517 -LP, and KIF20A 809-833  -LP) were synthesized (MBL, Nagoya, Japan; purity >95%; Supplementary Fig. S1B ). A human immunodeficiency virus (HIV) peptide that binds to HLA-A24 (HIV-A24) was used as a negative control SP (17) . A WT1-derived LP presented by HLA-DR4 (WT1-peptide) and a promiscuous HIV-derived LP were used as negative control LPs (20, 21) . Peptides were dissolved in dimethylsulfoxide at 10 mg/mL. The recombinant whole KIF20A and CDCA1 protein were expressed by Escherichia coli BL21 with a pET28a vector (Novagen). The CDCA1 protein was used as a control. Each recombinant protein was purified and assessed by SDS-PAGE.
Synthetic peptides and recombinant proteins
Generation of antigen-specific CD4
þ T cells from healthy donors The research protocol for collecting and using PBMCs from healthy donors (HD1-HD11; Supplementary Table  S2) was approved by the Institutional Review Board of Kumamoto University. We obtained PBMCs from 11 healthy donors with written informed consent. Genotyping of HLA-A, DRB1, and DPB1 was conducted at the HLA Laboratory (Kyoto, Japan; Supplementary Table S2) . With some modifications, induction of antigen-specific CD4 þ T cells was conducted as described previously (22) . Detailed methods are provided in Supplementary Materials and Methods. In some instances, T cells were cloned by limiting dilution for further studies as described previously (23) .
Assessment of T-cell responses to peptides and proteins
The immune response of T H cells to APCs pulsed with peptides (10 mg/mL) or proteins (50 mg/mL) was assessed by IFN-g enzyme-linked immunospot (ELISPOT) assays (BD Biosciences) as described previously (17) . In brief, the frequency of peptide-specific CD4 þ T cells producing [24] [25] [26] . All mAbs were used at a final concentration of 5 mg/mL. All assessments of IFN-g ELISPOT assays were conducted in triplicate or duplicate, and results are presented as means AE SD.
Immunohistochemical examination
Immunohistochemical staining of KIF20A using a rabbit polyclonal antibody against KIF20A (A300-879A, Bethyl Laboratories) was conducted as described previously (1, 2, 27 Peptide-stimulated degranulation of CD4 þ T lymphocytes was determined by flow cytometric analysis of CD107a exposed on the cell surface as described previously, with some modifications (28) . Detailed methods are provided in Supplementary Materials and Methods.
The synergistic effect of KIF20A-LPs on induction of KIF20A-specific CTLs PBMCs obtained from an HLA-A2
, from whom the KIF20A 60-84 -LP or KIF20A 809-833 -LP-specific T H clones were generated, were plated in 24-well plates (3 Â 10 6 cells/well), followed by addition of SP alone (KIF20A-A2 809-817 SP, 20 mg/mL), or SP þ LP (KIF20A 60-84 -LP or KIF20A 809-833 -LP, 20 mg/mL), or SP þ LP þ Th-clone (5 Â 10 5 cells/well) in a final volume of 2 mL. After culture for 7 days, these peptides and IL-2 (20 U/mL) were added, then IL-15 (5 ng/mL) was added on day 9. On day 11, cells were stained with phycoerythrin-labeled tetramer of the HLA-A Ã 02:01/KIF20A-A2 809-817 -complex and a fluorescein isothiocyanate-labeled anti-human CD8 mAb. Data acquisition was conducted on a FACSCalibur (BD Biosciences), and data files were analyzed with FlowJo software (Tree Star).
In vitro stimulation of KIF20A-A2 809-817 SP-specific CTLs with KIF20A 809-833 -LP Induction of KIF20A-A2 809-817 SP-reactive bulk CTLs from an HLA-A2 þ and DR53 þ donor (HD5) by stimulation with KIF20A-A2 809-817 SP was conducted as described (28, 29) . In brief, purified human CD8 þ T cells were stimulated with KIF20A-A2 809-817 SP-pulsed dendritic cells. After 3 rounds of stimulation, we confirmed that CTLs specifically produced IFN-g in response to restimulation with T2 cells pulsed with KIF20A-A2 809-817 SP; thus, the KIF20A-A2 809-817 SP-reactive CTLs were used as effector cells.
To prove the stimulation of KIF20A-A2 809-817 SP-reactive CTLs with KIF20A 809-833 -LP-loaded dendritic cells, the number of IFN-g producing KIF20A-A2 809-817 SPspecific bulk CTLs in response to stimulation with the KIF20A 809-833 -LP-loaded autologous dendritic cells was counted by an ELISPOT assay. The LP-loaded mature dendritic cells were prepared from positively isolated CD14 þ cells (day 0). CD14 þ cells were cultured in the presence of IL-4 (10 ng/mL) and GM-CSF (100 ng/mL). KIF20A 809-833 -LP (50 mg/mL) and OK432 were added on day 5. The LPloaded mature dendritic cells were harvested on day 7, washed, and used as APCs in an ELISPOT assay.
Assessment of KIF20A-LPs-specific CD4 þ T-cell responses in patients with HNMT Fresh PBMCs from patients with HNMT or healthy donors were cultured with a mixture of KIF20A 60-84 -LP and KIF20A 809-833 -LP (10 mg/mL each) in a final volume of 2 mL AIM-V supplemented with 5% human decomplemented plasma at 37 C (2 Â 10 6 cells/well, 24-well plates); both recombinant human (rh) IL-2 and rhIL-7 were added on day 0 and 2. After 1 week of cell culture, the PBMCs were collected, washed, and cultured in ELISPOT plates (1 Â 10 5 cells/well) with KIF20A 60-84 -LP, KIF20A 809-833 -LP, or control LP for 18 hours. The number of KIF20A-LP-specific T H cells expressed as spot-forming cells/10 5 cells was calculated after subtracting control values (background). Responses were scored as positive when the mean number of IFN-g spots was more than 15 and more than twofold over background. The ELISPOT assays on patients' cells were conducted in single, duplicate, or triplicate wells because of the limited number of available cells. This study was conducted in a laboratory that operates under exploratory research principles, and was conducted using investigative protocols. We acknowledge the recommendations of the Minimal Information About T-cell Assays reporting framework for human T-cell assays (30) .
Statistical analysis
Data were compared by the two-tailed Student t test (bar graphs), or by the nonparametric Mann-Whitney U test (scatter-dot graph). Differences with a P value < 0.05 were considered statistically significant for all tests.
Results
Prediction and selection of possible promiscuous HLA class II-binding KIF20A-LPs
To identify possible promiscuous HLA class II-binding T H -cell epitopes of KIF20A, we first examined the amino acid sequence of KIF20A using a recently developed computer algorithm (Supplementary Fig. S1A ; refs. 18 and 19). Two LPs, KIF20A 60-84 -LP and KIF20A 809-833 -LP, predicted by the computer algorithm to be potent promiscuous HLA class II-binding peptides, were identified proximal to known 9-or 10-mer CTL epitopes recognized by HLA-A2-or A24-restricted CTLs (Supplementary Fig. S1B and Table S1 ). Another peptide, KIF20A 494-517 -LP, was also predicted to be a potent promiscuous HLA class II-binding peptide, although it did not include a known CTL-epitope sequence. Therefore, 3 Fig. S2C ). Although the immunogenicity of KIF20A 494-517 -LP was assessed in other donors, it was less immunogenic. Thus, we focused on promiscuous LPs bearing known CTL epitopes, such as KIF20A 60-84 -LP and KIF20A 809-833 -LP, for further studies.
KIF20A 60-84 -LP and KIF20A 809-833 -LP are naturally processed and presented by dendritic cells We proceeded to assess whether dendritic cells take up and process the KIF20A protein to stimulate KIF20A-specific T H clones. Dendritic cells loaded with recombinant KIF20A protein were prepared and used as APCs in IFN-g ELISPOT assays (16, 28 ). An HLA-DP2-restricted KIF20A 60-84 -LPspecific T H clone efficiently recognized dendritic cells loaded with KIF20A protein in an HLA-DP-dependent manner, but did not recognize control protein-loaded dendritic cells, indicating that this epitope was naturally processed and presented by HLA-DP2 molecules ( Fig. 2A ). An HLA-DR53-restricted KIF20A 809-833 -LP-specific T H clone efficiently recognized dendritic cells loaded with KIF20A protein in an HLA-DR-dependent manner, but did not recognize control protein-loaded dendritic cells, indicating that this epitope was also naturally processed and presented by HLA-DR53 molecules (Fig. 2B) .
KIF20A-LPs stimulate T H 1-type CD4
þ T cells
To further characterize KIF20A-LP-reactive T H cells, we used the Bio-Plex system to measure the levels of several cytokines released in response to stimulation by the cognate peptide. KIF20A 60-84 -LP-or KIF20A 809-833 -LP-specific bulk T H cells from HD2 produced a large amount of TNF-a, IFN-g, GM-CSF, MIP-1b, and IL-2, but less IL-4 and IL-17 after restimulation with cognate peptide, indicating T H 1-polarized characteristics (Fig. 3A) . The cytotoxicity marker CD107a was detected on the KIF20A-LPs-specific bulk T H cells stimulated with cognate peptide (Fig. 3B) , as was previously showed for antiviral CD4 þ effectors and tumor-infiltrating lymphocytes (33) (34) (35) (36) . These data suggest that KIF20A-specific T H cells provide a helper function and direct cytotoxic activity, both of which are advantageous for cancer immunotherapy.
Enhanced induction of KIF20A-specific CTLs by KIF20A-LP-specific CD4 þ T cells Supplementary  Fig. S3D ). These results suggest that activated KIF20A-LPspecific T H cells enhance induction of KIF20A-A24 66-75 SPspecific CTLs expressing CD107a.
KIF20A-LPs stimulate KIF20A-specific CD8 þ T-cells in vitro and in vivo
We assessed whether the KIF20A-LPs bearing CTL epitopes could stimulate KIF20A-SP-specific CTLs. The capacity of KIF20A 809-833 -LP to stimulate KIF20A-A2 809-817 SPspecific CTLs was examined by IFN-g ELISPOT assay as described in the Materials and Methods section. As shown in Table S3 ). No staining was detected in the benign tumor samples. In context of cancer immunotherapy, there is strong evidence suggesting that vaccines using restricted epitopes can result in broad CD8
þ T-cell responses to antigens not presented in the vaccine (37) (38) (39) . Thus, we considered that KIF20A-specific T H -cell responses may be induced by vaccination with TAA-derived CTL-epitope peptides, which do not include KIF20A-derived SPs. We assessed T-cell responses specific for KIF20A in peripheral blood from 16 patients who were receiving immunotherapy for treatment of HNMT. The donor characteristics are summarized in Table 1 . After 1 week of in vitro stimulation of PBMCs with KIF20A-LPs, the frequency of individual KIF20A-LP-specific T cells was detected by IFN-g ELISPOT assay (Fig. 5A ). PBMCs isolated from 9 healthy volunteers were used as controls. Responses were considered positive when the number of IFN-g-secreting cells was at least twofold above the negative control. KIF20A-specific T H -cell responses were observed in 8 of 16 patients (KIF20A 60-84 -LP, 2 of 16, 13%; KIF20A 809-833 -LP, 7 of 16, 44%), but no specific immune responses to KIF20A-LPs were detected in the 9 healthy donors (Table 1) . We also found that the number of specific spots against KIF20A 60-84 -LP and KIF20A 809-833 -LP in patients were significantly larger than in healthy donors (Fig. 5B) . KIF20A 809-833 -LP-specific IFN-g production by T cells in HNMT31 and HNMT43 was significantly inhibited by addition of anti-HLA-DR mAb but not by anti-HLA class I mAb (Fig. 5C ). Interestingly, specific responses to KIF20A 809-833 -LP were augmented in some patients (HNMT31 and HNMT42), or induced in HNMT43 during the course of immunotherapy (Fig. 5D ). As shown in Fig.  5E , KIF20A antigen was expressed in patients with HNMT in whom KIF20A-specific T H 1 cell responses were detected (Table 1; HNMT31 and HNMT108), but was not expressed in those for whom KIF20A-specific T H 1 cell responses were not detected (Table 1 ; HNC102 and 107). These observations suggest that APCs collected and processed a KIF20A antigen derived from tumor cells expressing KIF20A, and then activated KIF20A-specific T H 1 cells in vivo.
Discussion
We identified 2 promiscuous KIF20A-derived T H -cell epitopes bearing known HLA-A2-or HLA-A24-restricted CTL epitopes. KIF20A-specific CTLs were induced by stimulation with KIF20A-LPs in vitro and in vivo. This is the first demonstration of KIF20A expression in HNMT, and the presence of KIF20A-specific T H 1-cell responses in patients with HNMT. Furthermore, these responses were related to KIF20A expression in HNMT tissues. We postulate that these KIF20A-LPs-specific T H 1-cell responses may occur through the KIF20A antigen in apoptotic bodies released from tumor cells. When collected and processed by APCs, the KIF20A antigen most probably activates KIF20A-specific T H 1 cells in vivo.
Recent reports showed that a new wave of tumor-specific CTL clones became detectable in the blood after vaccination and provide convincing evidence that the phenomenon of antigen spreading is critical to the development of effective antitumor immunity (37) (38) (39) (40) (41) . The interaction between antivaccine CTLs and the tumor facilitates stimulation of large numbers of antitumor CTLs that proceed to destroy the tumor cells. However, CD4
þ T-cell responses against a TAA in tumor-bearing patients vaccinated with CTL-epitope peptides have not been investigated in detail. In this study, we analyzed CD4 þ T-cell responses to a KIF20A antigen, which was not present in the vaccine cocktail, in the patient's blood before and after vaccination to investigate the phenomenon of antigen spreading triggered by CTLepitope vaccination. In patient HNMT43 with advanced cancer, the KIF20A 809-833 -LP-specific T H 1 response was absent before vaccination, but after vaccination this response was significantly induced (Fig. 5D, right panel) . We believe that this KIF20A 809-833 -LP-specific T H 1-cell response is a phenomenon of antigen spreading triggered by vaccination with CTL epitopes. Aarntzen and colleagues have recently reported that targeting T H cells with dendritic cells pulsed with both HLA class I-and II-restricted epitopes enhances vaccine-specific immunologic responses and improves clinical responses (42) . We showed that KIF20A-LPs and T H 1 clones enhanced induction of HLA-A2-restricted KIF20A-specific CTLs in vitro. These findings indicate that KIF20A-LPs can augment the induction of antigen-specific CTLs in combination with immunotherapy using KIF20A CTL-epitope peptides. We speculate that immunotherapy with peptide vaccinations using KIF20A-LPs and KIF20A-SPs may improve clinical outcomes in KIF20A-expressing cancer.
HLA class II restriction of the KIF20A 809-833 -LP-specific CD4 þ T-cell response in HNMT31 was confirmed by inhibition of IFN-g secretion in the presence of HLA-DR-blocking antibody (Fig. 5C ), although HLA-DR alleles of HNMT31 (Table 1 ; DRB1 Ã 01:01/11:01) were not shared by the HLA-DR alleles, which encode HLA class II molecules presenting KIF20A 809-833 -LP to T H cells in healthy donors (HLA-DR15 and DR53; Fig. 1 ). This result supports the promiscuous nature of KIF20A 809-833 -LP and indicates that LP is naturally processed and presented by HLA class II molecules in vivo.
In this study, significant frequencies of KIF20A-specific T H 1-cell responses were detected in patients with HNMT receiving immunotherapy (8 of 16, 50%). Godet and colleagues reported a possible synergistic effect of the telomerase-specific CD4 þ T-cell response with chemotherapy in lung cancer. They showed that the existence of spontaneous telomerase-specific T H 1 cells before first-line chemotherapy significantly increased overall survival in lung cancer that responded to chemotherapy (43) . In addition, the recent introduction of immunotherapy in clinical practice emphasized the influence of immune responses on cancer prognosis and chemotherapy effectiveness (11, 12, 44) . These pieces of evidence support the hypothesis that induction of KIF20A-specific T H 1 cells by KIF20A-LP vaccination may improve the clinical outcome of cancer patients when combined with chemotherapy or other standard therapies 
